Aptose to Release Fourth Quarter and Year End December 31, 2019 Financial Results and Hold Conference Call on March 10, 2020
February 25, 2020 07:31 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference
January 29, 2020 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences to Present at Biotech Showcase™ 2020 Conference
January 07, 2020 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Announces Closing of Public Offering of Common Shares
December 19, 2019 16:02 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced...
Aptose Announces Pricing of Public Offering of Common Shares
December 17, 2019 08:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced...
Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting
December 09, 2019 11:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Aptose Presents Highlights From Corporate Event At ASH
December 07, 2019 11:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO, TORONTO and ORLANDO, Fla., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a corporate event and clinical update today held at...
Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer
December 04, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference
December 02, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Reports Results for the Third Quarter Ended September 30, 2019
November 05, 2019 16:02 ET
|
Aptose Biosciences, Inc.
CG-806 Mutation Agnostic FLT3/BTK Inhibitor and APTO-253 MYC Inhibitor Safely Dose Escalate CLL Patient Treated with Second Dose Level of CG-806 Shows Evidence of Clinical Response Conference Call...